Asthma News and Research

RSS

Asthma is a common inflammatory disease affecting the airways that leads to shortness of breath, coughing and wheezing. Symptoms range from mild to severe but are generally manageable with appropriate treatment.

Non-adherence to medication may be the cause for difficult asthma

Difficult-to-treat asthma often may have more to do with patients who do not take their medication as instructed than ineffective medication, according to researchers in Northern Ireland.

23 Oct 2009

Report: Quality of care for insured Americans slipped in 2008

CNNMoney reports that for the first time in more than 10 years, the "overall quality of health care" for Americans insured through commercial and public plans appears to have slipped.

23 Oct 2009

Majority of allergy patients can be vaccinated against swine flu after evaluation by an allergist

Once supply catches up with the immediate demand for H1N1 "swine" flu vaccine, some allergy patients who could benefit from the vaccine may needlessly avoid it due to confusion over who should, and should not, be vaccinated, cautions Dr. Peter R. Smith, a board-certified allergist and clinical immunologist with Allergy Partners of Fredericksburg, Virginia.

23 Oct 2009

Merck's sales increases by 2% in third quarter 2009

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.

22 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

New procurement guidelines to minimize formaldehyde and VOCs exposure

To minimize formaldehyde and exposure to other volatile organic compounds (VOCs) in emergency housing, FEMA developed new procurement guidelines for allowable airborne levels in manufactured housing.

22 Oct 2009

ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve

ISTA Pharmaceuticals, Inc. today announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.

22 Oct 2009

Optimized mouthpiece design reduces wastage of medication

Researchers have developed an optimized mouthpiece design to aid efficient drug delivery to the lungs by reducing the amount of medication wasted as it passes through the mouthpiece of an aerosol inhaler.

22 Oct 2009

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that The Children's Hospital of Philadelphia (CHOP), one of the leading pediatric hospitals and research facilities in the world, has implemented the InforSense-based Translational Research Solution to advance the understanding of complex genetic disease.

22 Oct 2009

Health Impact Project to promote the use of health impact assessments

The Robert Wood Johnson Foundation (RWJF) and The Pew Charitable Trusts (Pew) today announced the launch of the Health Impact Project, a national initiative designed to promote the use of health impact assessments (HIAs) as a decision-making tool for policymakers.

21 Oct 2009

BioWa, NKT Therapeutics sign licensing agreement

BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

21 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.

20 Oct 2009

AAP's initiative to address childhood asthma

With chronic diseases on the rise in children, pediatricians are looking for solutions to improve care and outcomes for these often complex illnesses. The American Academy of Pediatrics (AAP) today announced a new initiative funded with a grant from the Merck Childhood Asthma Network, Inc. (MCAN) that will allow pediatricians across the country to pilot a series of quality improvement programs to effectively address the top chronic disease affecting kids - childhood asthma.

20 Oct 2009

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

20 Oct 2009

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.

19 Oct 2009

SequelMed Patient Portal launched by Sequel Systems

Sequel Systems, Inc., a dynamic, service-oriented healthcare technology company, today announced the launch and general availability of SequelMed Patient Portal™, a new, Web-based tool that improves and speeds up communication between physicians and patients, giving patients instant access to their personal health information, and allowing physicians and other healthcare providers more time to focus on delivering the best possible care. SequelMed Patient Portal is the latest addition to Sequel Systems’ suite of healthcare solutions, which includes an electronic health record (EHR), practice and document management software, and e-prescribing technology. More than 12,000 physicians in all 50 states and representing all major specialties currently use the company’s solutions.

19 Oct 2009

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Cannabis Science Inc., an emerging pharmaceutical cannabis company, notes a report by epidemiologists at the Centers for Disease Control and Prevention (CDC) saying that, among people hospitalized with severe cases of the pandemic strain of H1N1 Swine Flu, asthma is by far the most common underlying condition associated with he disease.

19 Oct 2009

Qforma introduces new phase of its healthcare database

Patients diagnosed with breast cancer or depression who are seeking a medical expert in their own community to guide them through treatment now have a place to start. Qforma, an advanced analytics and predictive modeling company, today introduced the new phase of its first-of-its-kind healthcare database "Most Influential Doctors," or MID, presented by USA TODAY.

19 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Asthma News and Research

Further Reading

Non-adherence to medication may be the cause for difficult asthma

Report: Quality of care for insured Americans slipped in 2008

Majority of allergy patients can be vaccinated against swine flu after evaluation by an allergist

Merck's sales increases by 2% in third quarter 2009

Schering-Plough announces 2009 third quarter financial results

New procurement guidelines to minimize formaldehyde and VOCs exposure

ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve

Optimized mouthpiece design reduces wastage of medication

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

Health Impact Project to promote the use of health impact assessments

BioWa, NKT Therapeutics sign licensing agreement

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

AAP's initiative to address childhood asthma

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

SequelMed Patient Portal launched by Sequel Systems

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Qforma introduces new phase of its healthcare database

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News